使用白细胞介素-17A抗体司库奇尤单抗治疗急性泛发性脓疱型银屑病。 - Suppr

Suppr

超能文献

Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.

作者信息

Böhner Alexander, Roenneberg Sophie, Eyerich Kilian, Eberlein Bernadette, Biedermann Tilo

机构信息

Department of Dermatology and Allergy Biederstein, Technical University Munich, Munich, Germany.

出版信息

JAMA Dermatol. 2016 Apr;152(4):482-4. doi: 10.1001/jamadermatol.2015.4686.

DOI:10.1001/jamadermatol.2015.4686

PMID:26650014

Abstract

摘要

相似文献

Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.

JAMA Dermatol. 2016 Apr;152(4):482-4. doi: 10.1001/jamadermatol.2015.4686.

Safety of secukinumab in the treatment of psoriasis.

Expert Opin Drug Saf. 2016 Oct;15(10):1413-20. doi: 10.1080/14740338.2016.1221923. Epub 2016 Aug 22.

Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.

J Dermatol. 2018 Jul;45(7):850-854. doi: 10.1111/1346-8138.14318. Epub 2018 Apr 14.

Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.

J Dermatol. 2018 Nov;45(11):1353-1356. doi: 10.1111/1346-8138.14636. Epub 2018 Sep 19.

Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.

Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):153-66. doi: 10.1586/14737167.2016.1133301. Epub 2016 Feb 2.

Secukinumab: a review in moderate to severe plaque psoriasis.

Am J Clin Dermatol. 2015 Aug;16(4):323-330. doi: 10.1007/s40257-015-0143-7.

Secukinumab (AIN-457) for the treatment of Psoriasis.

Expert Rev Clin Pharmacol. 2016;9(2):187-202. doi: 10.1586/17512433.2016.1129894.

Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.

Med Lett Drugs Ther. 2017 Jul 17;59(1525):118-119.

IL-17 inhibitors for psoriasis.

Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.

A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.

Expert Opin Investig Drugs. 2016 Nov;25(11):1337-1344. doi: 10.1080/13543784.2016.1237502. Epub 2016 Sep 30.

引用本文的文献

Considerations for defining and diagnosing generalized pustular psoriasis.

J Eur Acad Dermatol Venereol. 2025 Mar;39(3):487-497. doi: 10.1111/jdv.20310. Epub 2024 Sep 6.

Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date.

Psoriasis (Auckl). 2024 Mar 15;14:23-27. doi: 10.2147/PTT.S393978. eCollection 2024.

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Clin Cosmet Investig Dermatol. 2023 Jun 28;16:1677-1690. doi: 10.2147/CCID.S407812. eCollection 2023.

Chronic annular pustular psoriasis resembling subcorneal pustular dermatosis: A case report.

SAGE Open Med Case Rep. 2019 Jun 20;7:2050313X19857392. doi: 10.1177/2050313X19857392. eCollection 2019.

Secukinumab in Generalized Pustular Psoriasis.

Indian Dermatol Online J. 2018 Nov-Dec;9(6):464-466. doi: 10.4103/idoj.IDOJ_93_18.

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.

JAAD Case Rep. 2018 Sep 19;4(8):842-844. doi: 10.1016/j.jdcr.2018.03.016. eCollection 2018 Sep.

Pustular psoriasis: pathophysiology and current treatment perspectives.

Psoriasis (Auckl). 2016 Sep 12;6:131-144. doi: 10.2147/PTT.S98954. eCollection 2016.

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

MAbs. 2017 Oct;9(7):1143-1154. doi: 10.1080/19420862.2017.1353853. Epub 2017 Jul 20.

IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.

J Allergy Clin Immunol. 2017 Jul;140(1):109-120. doi: 10.1016/j.jaci.2016.08.056. Epub 2016 Dec 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.

JAMA Dermatol. 2016 Apr;152(4):482-4. doi: 10.1001/jamadermatol.2015.4686.

Safety of secukinumab in the treatment of psoriasis.

Expert Opin Drug Saf. 2016 Oct;15(10):1413-20. doi: 10.1080/14740338.2016.1221923. Epub 2016 Aug 22.

Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.

J Dermatol. 2018 Jul;45(7):850-854. doi: 10.1111/1346-8138.14318. Epub 2018 Apr 14.

Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.

J Dermatol. 2018 Nov;45(11):1353-1356. doi: 10.1111/1346-8138.14636. Epub 2018 Sep 19.

Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.

Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):153-66. doi: 10.1586/14737167.2016.1133301. Epub 2016 Feb 2.

Secukinumab: a review in moderate to severe plaque psoriasis.

Am J Clin Dermatol. 2015 Aug;16(4):323-330. doi: 10.1007/s40257-015-0143-7.

Secukinumab (AIN-457) for the treatment of Psoriasis.

Expert Rev Clin Pharmacol. 2016;9(2):187-202. doi: 10.1586/17512433.2016.1129894.

Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.

Med Lett Drugs Ther. 2017 Jul 17;59(1525):118-119.

IL-17 inhibitors for psoriasis.

Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.

A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.

Expert Opin Investig Drugs. 2016 Nov;25(11):1337-1344. doi: 10.1080/13543784.2016.1237502. Epub 2016 Sep 30.

引用本文的文献

Considerations for defining and diagnosing generalized pustular psoriasis.

J Eur Acad Dermatol Venereol. 2025 Mar;39(3):487-497. doi: 10.1111/jdv.20310. Epub 2024 Sep 6.

Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date.

Psoriasis (Auckl). 2024 Mar 15;14:23-27. doi: 10.2147/PTT.S393978. eCollection 2024.

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Clin Cosmet Investig Dermatol. 2023 Jun 28;16:1677-1690. doi: 10.2147/CCID.S407812. eCollection 2023.

Chronic annular pustular psoriasis resembling subcorneal pustular dermatosis: A case report.

SAGE Open Med Case Rep. 2019 Jun 20;7:2050313X19857392. doi: 10.1177/2050313X19857392. eCollection 2019.

Secukinumab in Generalized Pustular Psoriasis.

Indian Dermatol Online J. 2018 Nov-Dec;9(6):464-466. doi: 10.4103/idoj.IDOJ_93_18.

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.

JAAD Case Rep. 2018 Sep 19;4(8):842-844. doi: 10.1016/j.jdcr.2018.03.016. eCollection 2018 Sep.

Pustular psoriasis: pathophysiology and current treatment perspectives.

Psoriasis (Auckl). 2016 Sep 12;6:131-144. doi: 10.2147/PTT.S98954. eCollection 2016.

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

MAbs. 2017 Oct;9(7):1143-1154. doi: 10.1080/19420862.2017.1353853. Epub 2017 Jul 20.

IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.

J Allergy Clin Immunol. 2017 Jul;140(1):109-120. doi: 10.1016/j.jaci.2016.08.056. Epub 2016 Dec 31.